We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Butterfly Network (BFLY - Free Report) recently announced the availability of its first specialty product, the iQ+ Bladder, in the United States. This launch marks a significant expansion for Butterfly, as it moves beyond its traditional point-of-care ultrasound offerings to cater to the bladder scanning market. The iQ+ Bladder is a comprehensive solution that includes a specialized probe, software, a compact rolling cart, a tablet and a power splitter, all designed to streamline the bladder scanning process using ultrasound.
The iQ+ Bladder offers a purpose-built, streamlined solution for bladder scanners that helps nurses get automated bladder volume calculations, with 3D visualizations, in seconds.
The stock has declined 3.7% year to date compared with the industry’s 16.6% decline. The S&P 500 Index has increased 10.3% in the same period.
Image Source: Zacks Investment Research
Innovative Technology for Enhanced Patient Care
At the heart of the iQ+ Bladder is Butterfly's proprietary Ultrasound-on-Chip technology, which powers the specialized probe. This technology ensures durability for daily use, making it a reliable tool for healthcare professionals. The probe is complemented by intuitive software that is specifically tailored to the needs of nurses and other providers who perform bladder scans regularly. The software's user-friendly interface eliminates the need for complex configurations, thereby allowing for quick and intuitive scans.
The solution provides automated bladder volume calculations with 3D visualizations, enabling nurses to obtain accurate measurements in seconds. Additionally, the compact rolling cart includes storage space and a probe charging dock, ensuring that the equipment is always ready for use. The large tablet mounted on the cart can be adjusted for optimal viewing, thus further enhancing the user experience.
The introduction of the iQ+ Bladder addresses key challenges faced by healthcare professionals, including the need for efficient, reliable and cost-effective bladder scanning solutions. With its emphasis on efficiency, ease of use and workflow optimization, the iQ+ Bladder has the potential to streamline clinical processes, enhance patient care and drive value for healthcare organizations.
Impact on Butterfly Network
The launch of the iQ+ Bladder represents a strategic move for Butterfly Network, expanding its market reach and solidifying its position as a leader in portable ultrasound technology. By entering the bladder scanning market, Butterfly has demonstrated its ability to adapt to evolving healthcare needs and diversify its product offerings. This expansion is likely to have a positive impact on Butterfly's growth and market presence, further establishing the company as a key player in the digital health industry.
DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 29.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have risen 30.3% compared with the industry’s 9.5% growth year to date.
Medpace, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 17.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.8%.
Medpace’s shares have risen 27% year to date compared with the industry’s 3.5% growth.
Align Technology, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed the same in one quarter, delivering an average surprise of 5.9%.
ALGN’s shares have declined 0.5% year to date against the industry’s 2.3% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Butterfly Network (BFLY) Unveils iQ+ Bladder Ultrasound Scanner
Butterfly Network (BFLY - Free Report) recently announced the availability of its first specialty product, the iQ+ Bladder, in the United States. This launch marks a significant expansion for Butterfly, as it moves beyond its traditional point-of-care ultrasound offerings to cater to the bladder scanning market. The iQ+ Bladder is a comprehensive solution that includes a specialized probe, software, a compact rolling cart, a tablet and a power splitter, all designed to streamline the bladder scanning process using ultrasound.
The iQ+ Bladder offers a purpose-built, streamlined solution for bladder scanners that helps nurses get automated bladder volume calculations, with 3D visualizations, in seconds.
The stock has declined 3.7% year to date compared with the industry’s 16.6% decline. The S&P 500 Index has increased 10.3% in the same period.
Image Source: Zacks Investment Research
Innovative Technology for Enhanced Patient Care
At the heart of the iQ+ Bladder is Butterfly's proprietary Ultrasound-on-Chip technology, which powers the specialized probe. This technology ensures durability for daily use, making it a reliable tool for healthcare professionals. The probe is complemented by intuitive software that is specifically tailored to the needs of nurses and other providers who perform bladder scans regularly. The software's user-friendly interface eliminates the need for complex configurations, thereby allowing for quick and intuitive scans.
The solution provides automated bladder volume calculations with 3D visualizations, enabling nurses to obtain accurate measurements in seconds. Additionally, the compact rolling cart includes storage space and a probe charging dock, ensuring that the equipment is always ready for use. The large tablet mounted on the cart can be adjusted for optimal viewing, thus further enhancing the user experience.
The introduction of the iQ+ Bladder addresses key challenges faced by healthcare professionals, including the need for efficient, reliable and cost-effective bladder scanning solutions. With its emphasis on efficiency, ease of use and workflow optimization, the iQ+ Bladder has the potential to streamline clinical processes, enhance patient care and drive value for healthcare organizations.
Impact on Butterfly Network
The launch of the iQ+ Bladder represents a strategic move for Butterfly Network, expanding its market reach and solidifying its position as a leader in portable ultrasound technology. By entering the bladder scanning market, Butterfly has demonstrated its ability to adapt to evolving healthcare needs and diversify its product offerings. This expansion is likely to have a positive impact on Butterfly's growth and market presence, further establishing the company as a key player in the digital health industry.
Butterfly Network, Inc. Price
Butterfly Network, Inc. price | Butterfly Network, Inc. Quote
Zacks Rank & Other Stocks to Consider
Butterfly Network currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Align Technology (ALGN - Free Report) and Medpace (MEDP - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 13.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 29.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have risen 30.3% compared with the industry’s 9.5% growth year to date.
Medpace, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 17.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.8%.
Medpace’s shares have risen 27% year to date compared with the industry’s 3.5% growth.
Align Technology, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 6.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed the same in one quarter, delivering an average surprise of 5.9%.
ALGN’s shares have declined 0.5% year to date against the industry’s 2.3% growth.